We are a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs through epigenetic mechanisms. Such drugs are intended to provide patients with innovative treatment options that are more tolerable and efficacious than existing therapies and provide a better quality of life.

Our pipeline is protected by a comprehensive portfolio of patents and comprises promising products that are in various stages of preclinical and clinical development. Our aim is to generate future growth and enhance our enterprise value by entering into partnerships with pharmaceutical and biotech companies. 4SC AG has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.